Showing results (1761-1770 of 2,100) with videos related to

Sort By:
Pageof 210
Nature Communications|July 18, 2017
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapyAkane Inoue-Yamauchi, Paul S Jeng, Kwanghee Kim, et al.
Immunity & Ageing : I & A|November 3, 2022
Ageing-resembling phenotype of long-term allogeneic hematopoietic cells recipients compared to their donorsMichał Cezary Czarnogórski, Justyna Sakowska, Mateusz Maziewski, et al.
Journal for Immunotherapy of Cancer|February 3, 2024
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumorsSandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, et al.
Journal of Neurology|July 22, 2015
Frequent misdiagnosis of adult polyglucosan body diseaseMark A Hellmann, Or Kakhlon, Ezekiel H Landau, et al.
American Journal of Hematology|October 6, 2015
Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemiaYishai Ofran, Ronit Leiba, Chezi Ganzel, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Clinical ManifestationsLena Sannemann, Katharina Buerger, Julian Hellmann-Regen, et al.
The American Journal of Pathology|May 13, 2016
Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Protective for Injured EpitheliaJennifer K Colby, Raja-Elie E Abdulnour, Ho Pan Sham, et al.
Cancer Immunology Research|July 12, 2018
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLCFernando C Santini, Hira Rizvi, Andrew J Plodkowski, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2018
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032Neal Ready, Anna F Farago, Filippo de Braud, et al.
Pageof 210